secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0000920148-26-000135
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q1 revenue $3.54B (+5.8%), adjusted EPS $4.25 (+10.6%); raises FY guidance
--------------------------------------------------------------------------------

- Q1 diluted EPS $3.35 (+32.8% YoY); adjusted EPS $4.25 vs $3.84 consensus.
- FY2026 guidance raised: revenue growth 5.0%–6.1%, Adj. EPS $17.70–$18.35 (midpoint $18.03, +$0.13).
- Diagnostics revenue $2.76B (+5.0%); adjusted margin 16.6% (+30bps). Biopharma Labs revenue $780.6M (+8.2%).
- Operating cash flow $191.5M (vs $18.5M); free cash flow $70.5M (vs -$107.5M).
- Completed acquisition of Crouse Health lab assets; partnerships with CHOP, Illumina, Optum.ai, PathAI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/0000920148-26-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000135/lh-20260430.htm
  HTML page:      https://secwatch.observer/filing/0000920148-26-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer